Last updated: September 7, 2026
Cenobamate, marketed in the United States as Xcopri and in Europe as Ontozry, is one of the fastest-growing branded therapies for focal-onset seizures. SK Biopharm and its U.S. affiliate SK Life Science control the core commercial opportunity, while regional partners market the drug outside the United States. U.S. sales growth has been driven by strong prescription expansion, favorable seizure-control data, and conversion of patients from older antiseizure medicines.
The commercial risk profile is concentrated. Xcopri is SK Biopharm's principal revenue-generating product, and the company's financial trajectory depends heavily on continued U.S. penetration before generic or follow-on competition emerges. Patent protection is expected to extend beyond the statutory new chemical entity period, although the timing and scope of generic entry will depend on Orange Book listings, Paragraph IV challenges, patent-term adjustments, and potential settlements.
What is cenobamate and how is Xcopri used?
Cenobamate is an antiseizure medicine approved by the U.S. Food and Drug Administration for the treatment of partial-onset seizures in adults. Its pharmacology combines positive allosteric modulation of GABA-A receptors with inhibition of voltage-gated sodium currents. The dual mechanism distinguishes it from several established focal-seizure therapies.
Xcopri is administered once daily after a gradual titration period. The approved maintenance dosage is generally 200 mg once daily, with a maximum recommended dosage of 400 mg once daily. Rapid dose escalation is restricted because of the risk of serious hypersensitivity reactions, including drug reaction with eosinophilia and systemic symptoms.
The principal safety and prescribing issues are:
| Issue |
Commercial relevance |
| DRESS and hypersensitivity |
Requires slow titration and limits rapid switching |
| QT-shortening effect |
Restricts use in certain inherited or acquired cardiac conditions |
| Central nervous system adverse events |
Can affect tolerability and persistence |
| Drug interactions |
Dose adjustment may be required with phenytoin, phenobarbital, carbamazepine and other agents |
| Schedule V status |
Adds controlled-substance handling requirements in the United States |
The FDA approved Xcopri on Nov. 21, 2019, and SK Life Science launched the product in the United States in 2020 (FDA, 2019).
How large is the market for cenobamate?
Cenobamate addresses the focal-onset epilepsy segment, which is the largest major seizure category in adults. The relevant market includes both new prescriptions and switching patients who remain inadequately controlled on existing therapy.
The commercial opportunity is supported by several structural factors:
- A large population remains uncontrolled despite treatment with multiple antiseizure medicines.
- Focal epilepsy patients often cycle through several branded and generic therapies.
- Physicians value high seizure-freedom rates in refractory patients.
- Generic competition has reduced prices for older products but has not eliminated demand for differentiated branded therapies.
- Once-daily dosing supports adherence and simplifies combination treatment.
Cenobamate competes most directly with lacosamide, brivaracetam, perampanel, eslicarbazepine, oxcarbazepine and branded or generic formulations of lamotrigine, levetiracetam and carbamazepine.
How does cenobamate compare with competing focal-seizure drugs?
Cenobamate's principal advantage is efficacy in highly treatment-resistant patients. In randomized trials, the 200 mg and 400 mg doses produced materially higher responder and seizure-freedom rates than placebo in adults with uncontrolled focal seizures. The clinical positioning is therefore closer to a high-efficacy add-on therapy than to a broad first-line antiseizure product.
| Product |
Active ingredient |
Primary commercial position |
Generic status |
| Xcopri |
Cenobamate |
High-efficacy focal-seizure therapy |
No U.S. generic approval identified through the cited period |
| Vimpat |
Lacosamide |
Established focal-seizure therapy |
Generic available |
| Briviact |
Brivaracetam |
Adjunctive therapy with levetiracetam-like positioning |
Generic competition remains limited in some markets |
| Fycompa |
Perampanel |
Broad adjunctive focal and generalized seizure indication |
Generic pressure varies by jurisdiction |
| Aptiom |
Eslicarbazepine |
Once-daily focal-seizure therapy |
Generic and patent risks vary |
| Keppra |
Levetiracetam |
High-volume, low-cost foundational therapy |
Widely generic |
Cenobamate's efficacy creates pricing power, but its market is limited by the focal-onset indication, slow titration, safety monitoring and the availability of low-cost generic alternatives.
What is the financial trajectory for SK Biopharm and Xcopri?
Xcopri has moved from launch investment to the primary earnings driver for SK Biopharm. Company-reported consolidated revenue reached approximately KRW 547.7 billion in 2024, compared with approximately KRW 354.9 billion in 2023. The company reported approximately KRW 96.3 billion in 2024 operating profit, reflecting the operating leverage of a wholly owned U.S. commercial product after the launch infrastructure was established (SK Biopharmaceuticals, 2025).
| Metric |
2023 |
2024 |
Direction |
| SK Biopharm consolidated revenue |
Approximately KRW 354.9 billion |
Approximately KRW 547.7 billion |
Strong increase |
| Operating result |
Near break-even to modest profit |
Approximately KRW 96.3 billion operating profit |
Improved |
| Principal growth driver |
Xcopri U.S. sales |
Xcopri U.S. sales |
Concentration increased |
| Commercial phase |
Prescription expansion |
Scale and profitability |
Positive |
The financial trajectory has four phases:
Launch phase: 2020-2021
The product required physician education, payer access work and titration-based patient onboarding. Early revenue was constrained by the COVID-19 disruption to epilepsy care and physician visits.
Adoption phase: 2022-2023
Prescription growth accelerated as neurologists gained experience with the drug and clinical familiarity increased. The product began taking share from other branded adjunctive therapies, especially in refractory focal epilepsy.
Scale phase: 2024 onward
The U.S. organization achieved greater sales productivity, while the product's high gross margin supported rapid operating-profit expansion. Revenue growth increasingly reflects patient-base expansion rather than initial formulary access.
Mature-growth phase
The next stage depends on continued treatment duration, increased use by community neurologists and expansion into international markets. Growth will eventually moderate as the treated population becomes larger and earlier-line use reaches practical limits.
SK Biopharm's concentration risk is high because Xcopri provides the dominant share of product revenue. Any material safety signal, reimbursement restriction, competing efficacy data or accelerated generic entry would have an outsized effect on earnings.
When does cenobamate lose regulatory exclusivity?
The FDA granted Xcopri approval in November 2019. The five-year new chemical entity exclusivity period therefore ran through November 2024, subject to the precise FDA calculation and any applicable pediatric exclusivity. NCE exclusivity blocks submission of an ANDA or 505(b)(2) application relying on the product's safety and efficacy findings during the exclusivity period.
Patent protection is separate from regulatory exclusivity. A generic applicant can file an ANDA after applicable statutory barriers expire and can challenge listed patents through a Paragraph IV certification.
The practical generic-entry window is therefore governed by:
- FDA NCE and pediatric exclusivity;
- Orange Book-listed patents;
- patent-term adjustment or extension;
- the scope of method-of-use claims;
- formulation or dosage-regimen claims;
- Paragraph IV litigation;
- settlement terms;
- the generic applicant's ability to design around protected claims.
A precise first generic launch date cannot be inferred from the 2019 approval date alone.
What patents protect Xcopri and cenobamate?
Cenobamate's patent estate is expected to include composition-of-matter, pharmaceutical composition, treatment-method and dosage-regimen protection. The most important commercial patent is generally the core active-ingredient patent, because it can block ordinary pharmaceutical substitution across multiple indications.
The Orange Book determines which U.S. patents are formally listed against Xcopri. Relevant categories include:
| Patent category |
Protected subject matter |
Generic-entry significance |
| Composition of matter |
Cenobamate molecule and related chemical forms |
Broadest potential barrier |
| Pharmaceutical composition |
Drug-containing formulations and excipients |
May block specific products or formulations |
| Treatment method |
Use in focal-onset seizures and related patient populations |
Can support a skinny-label strategy if claims are carved out |
| Dose and titration regimen |
Specific initiation, escalation or maintenance schedules |
May be difficult to avoid where the labeled regimen is commercially important |
| Manufacturing process |
Synthesis, purification or solid-state control |
More relevant to supply and process litigation than ordinary ANDA substitution |
Public patent databases and Orange Book records should be read together. A patent family can contain overlapping U.S. continuations with different expiration dates and claim scope. The earliest expiration of one listed patent does not necessarily create an unrestricted launch opportunity if later patents remain enforceable.
What formulation patents protect cenobamate?
Formulation claims may cover tablet compositions, dosage strengths, release characteristics, stability profiles or specific excipient combinations. Xcopri is currently marketed as immediate-release oral tablets. Formulation patents are less powerful than a valid composition patent when a generic can use a different formulation, but they can delay approval or create litigation exposure if the generic product falls within the claims.
What method-of-use patents protect cenobamate?
Method patents may cover treatment of focal-onset seizures, seizure reduction, specific patient groups or dosing schedules. A generic applicant can seek approval with protected indications removed through a Section viii statement or a carved-out label. That strategy reduces the scope of method-of-use protection unless the patented use is difficult to avoid in ordinary prescribing practice.
Which companies are challenging Xcopri patents?
Generic companies can challenge Xcopri through Paragraph IV certifications after the statutory filing window opens. The relevant litigation questions are whether the challenged patent is valid, infringed and enforceable, and whether the generic applicant can launch at risk.
The competitive challenge may involve:
- large generic manufacturers with epilepsy portfolios;
- specialty generic companies targeting high-value branded products;
- 505(b)(2) applicants seeking a modified dosage form;
- authorized or licensed generic arrangements;
- patent settlements that provide a negotiated launch date.
A verified litigation record should be evaluated from the complaint, docket, Orange Book certifications and settlement filings rather than from a commercial database summary. The economic outcome can change materially if a settlement grants an early-entry date several years before the last nominal patent expiry.
What is the FDA regulatory status of cenobamate?
Xcopri has full FDA approval for adult partial-onset seizures. The product is not a biologic, so biosimilar substitution rules do not apply. Competition will arise through ANDAs or, for modified products, potentially through the 505(b)(2) pathway.
The absence of biosimilar risk is commercially important. A biologic may face multiple interchangeable or non-interchangeable follow-on products. Cenobamate instead faces conventional small-molecule generic substitution, with lower manufacturing barriers but greater exposure to automatic pharmacy substitution after approval.
The U.S. label includes a boxed warning for DRESS. The warning can slow adoption among some prescribers, but it also supports careful titration and patient monitoring rather than eliminating the product's use.
What generic launch risks exist for cenobamate?
The most likely launch scenarios are:
| Scenario |
Commercial impact |
| No Paragraph IV challenge before later patents expire |
Xcopri retains high margins for an extended period |
| Paragraph IV litigation with settlement |
Earlier but controlled erosion |
| At-risk generic launch after a court ruling |
Rapid price and volume pressure |
| Single generic entrant |
Moderate initial price erosion |
| Multiple generic entrants |
Faster price compression and pharmacy substitution |
| Skinny-label launch |
Selective competition in non-protected indications |
| Authorized generic |
Lower litigation risk but higher internal cannibalization |
The exposure is greater than for many older antiseizure drugs because Xcopri is a concentrated revenue asset. A single generic entrant could reduce net price, but the first entrant may also be constrained by manufacturing scale, controlled-substance distribution and physician reluctance to switch stable patients.
How strong is the cenobamate patent estate?
The patent estate is commercially strong if the core compound claims remain enforceable through the early 2030s and later formulation or regimen claims cover the marketed product. Its strength is weaker if generic applicants can avoid the listed claims through a different formulation, a carved-out label or an alternative titration schedule.
The main strengths are:
- high clinical differentiation;
- a single active ingredient with limited therapeutic substitutes at equivalent efficacy;
- substantial physician familiarity by the time generic entry occurs;
- potential layering of composition, formulation and regimen claims;
- high commercial value that supports sustained litigation investment.
The main weaknesses are:
- regulatory exclusivity has already expired;
- small-molecule generics face lower manufacturing barriers than biosimilars;
- focal-seizure indications can permit label carve-outs;
- generic applicants can challenge patents years before commercial launch;
- the company's revenue base is unusually concentrated in one product.
What licensing deals and geographic rights affect cenobamate?
SK Biopharm retains the core economic interest in cenobamate and commercializes the product in the United States through SK Life Science. Outside the United States, commercialization relies on regional partnerships and licensing arrangements.
Ontozry received European approval in 2021 for adjunctive treatment of focal-onset seizures in adults. Angelini Pharma has been associated with European commercialization under a partnership with SK Biopharm. Regional rights, regulatory timing and reimbursement decisions create different launch curves across Europe and other markets.
International revenue is strategically useful but is not yet equivalent to the U.S. opportunity. European pricing controls, health-technology assessment requirements and country-level reimbursement negotiations can extend the interval between regulatory approval and meaningful sales.
What is the outlook for cenobamate revenue?
The near-term outlook remains positive because the product is still expanding within a large undertreated focal-epilepsy population. Revenue growth should come from:
- higher new-patient starts;
- conversion from older branded therapies;
- use after failure of multiple antiseizure medicines;
- longer treatment persistence;
- broader neurologist adoption;
- international reimbursement expansion.
Growth risks include payer pressure, adverse-event concerns, competitive launches, generic filing activity and eventual patent litigation. The central investment variable is the duration of U.S. exclusivity, not the size of the underlying epilepsy market alone.
Key Takeaways
- Cenobamate is a high-efficacy focal-seizure therapy marketed as Xcopri in the United States and Ontozry in Europe.
- The FDA approved Xcopri in November 2019; its five-year NCE exclusivity period has ended, but patent protection may extend materially longer.
- SK Biopharm reported approximately KRW 547.7 billion in 2024 consolidated revenue and approximately KRW 96.3 billion in operating profit.
- Xcopri is the company's central commercial and earnings asset.
- The product competes against lacosamide, brivaracetam, perampanel, eslicarbazepine and generic antiseizure drugs.
- Biosimilar risk does not apply because cenobamate is a small molecule.
- Generic risk will depend on Orange Book patents, Paragraph IV litigation, settlements and the ability to carve out method-of-use claims.
- The most important commercial protection is the combination of clinical differentiation and layered patent coverage.
- The principal financial risk is concentrated exposure to U.S. Xcopri sales.
FAQs
Is cenobamate a biologic or a small-molecule drug?
Cenobamate is a small-molecule antiseizure drug. It is subject to conventional generic-drug pathways rather than biosimilar approval rules.
Is Xcopri approved as monotherapy?
The original U.S. approval was for adults with partial-onset seizures. Clinical use may expand through physician prescribing practice, but the labeled indication and any patent-protected use remain distinct questions.
Does cenobamate have orphan-drug exclusivity?
Regulatory exclusivity depends on the FDA designation and approval record. The principal commercial analysis should separate orphan exclusivity from NCE exclusivity and Orange Book patent protection.
How does Xcopri affect generic antiseizure-drug pricing?
Xcopri is likely to retain a premium while it has no approved generic substitute. Generic entry would pressure net price and could accelerate substitution, especially if multiple ANDA applicants launch.
Which company owns the cenobamate rights?
SK Biopharm developed cenobamate and retains the principal global economic interest. SK Life Science commercializes Xcopri in the United States, while regional partners handle selected international markets.
References
- Angelini Pharma. (2021). Ontozry receives European Commission approval for the adjunctive treatment of focal-onset seizures in adults.
- Food and Drug Administration. (2019). FDA approves new treatment for adults with partial-onset seizures. U.S. Department of Health and Human Services.
- Food and Drug Administration. (2024). Xcopri prescribing information. U.S. Department of Health and Human Services.
- Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
- Krauss, G. L., Sperling, M. R., Klein, P., Brandt, C., Lee, S. K., Milovanovic, M., et al. (2020). Safety and efficacy of adjunctive cenobamate for uncontrolled focal seizures: A randomized clinical trial. Neurology, 95(21), e2992-e3005.
- SK Biopharmaceuticals. (2025). 2024 annual results and investor relations materials. Seoul, South Korea.
- Sperling, M. R., Klein, P., Aboumatar, S., Grierson, L., Kalviainen, R., O'Brien, T. J., et al. (2020). Efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures: A multicenter, randomized, double-blind, dose-response trial. The Lancet Neurology, 19(1), 38-48.
